BRIEF published on 01/07/2026 at 19:17, 8 months 9 days ago ABIONYX Pharma's Half-Yearly Review of Liquidity Contract Liquidity Contract TP ICAP Europe Stock Market Transactions ABIONYX Pharma Stocks And Cash
PRESS RELEASE published on 01/07/2026 at 19:12, 8 months 9 days ago Inside Information / Other news releases ABIONYX Pharma releases half-yearly report on liquidity contract with TP ICAP (Europe) SA, detailing shares and cash balance for 2025 Liquidity Contract Shares TP ICAP Cash Balance ABIONYX Pharma
BRIEF published on 12/16/2025 at 21:23, 9 months ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
BRIEF published on 12/16/2025 at 21:23, 9 months ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 9 months ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 9 months 11 days ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 9 months 11 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 9 months 21 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 9 months 21 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 10 months 5 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
Published on 09/17/2026 at 13:00, 10 minutes ago Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 10 minutes ago Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 13:00, 10 minutes ago NiobiumX Mining Inc. Appoints Athabasca Basin Discovery Geologist Erik Sehn to Board of Directors
Published on 09/17/2026 at 12:00, 1 hour 10 minutes ago Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 3 hours 10 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/17/2026 at 13:05, 5 minutes ago Aurzen Expands Its Presence in Germany with Launch on Joybuy, Bringing EAZZE D1 and ZIP to More Consumers
Published on 09/17/2026 at 13:00, 10 minutes ago Original-Research: Smartbroker Holding AG (von GBC AG): BUY
Published on 09/17/2026 at 13:00, 10 minutes ago Medartis Group acquires M.A.R.C. Institute to establish its first surgical education center in the US
Published on 09/17/2026 at 13:00, 10 minutes ago Ascory Bank AG enters into a strategic, long-term partnership with Mount Street to deliver outsourced credit administration and surveillance
Published on 09/16/2026 at 17:45, 19 hours 25 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 6 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 19 hours ago Report on the Combined General Meeting of the 10th of September 2026
